Olatunji B. Alese
Advanced in Liver Cancer

Dr. Olatunji B. Alese

Oncology
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Offers Telehealth
26 Years of Experience

Advanced in Liver Cancer
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Olatunji Alese is an Oncologist in Atlanta, Georgia. Dr. Alese has been practicing medicine for over 26 years and is rated as an Advanced provider by MediFind in the treatment of Liver Cancer. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 1 clinical trial in the study of Liver Cancer.

Graduate Institution
University Of Ibadan, 2000.0
Residency
New York Medical College (Metropolitan Hospital Center)
Specialties
Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2016
Fellowships
Emory University School of Medicine
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322
Call: 404-778-1900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: HMPL-306
Study Phase: Phase 1
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug, Other
Study Drug: Romidepsin
Study Phase: Phase 1
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 11, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Hydroxychloroquine, Nab-paclitaxel, Paricalcitol
Study Phase: Phase 2
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

109 Total Publications

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal: JCO precision oncology
Published: October 16, 2025
View All 109 Publications
Similar Doctors
Nikita T. Amin
Advanced in Liver Cancer
Dr. Nikita T. Amin
Oncology | Hematology
Advanced in Liver Cancer
Dr. Nikita T. Amin
Oncology | Hematology

Piedmont Cancer Institute, PC

1800 Howell Mill Road Northwest, Suite 800, 
Atlanta, GA 
 (7.0 miles away)
404-350-9853
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nikita Amin is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Amin is rated as an Advanced provider by MediFind in the treatment of Liver Cancer. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Dehydration, and Chronic Familial Neutropenia. Dr. Amin is currently accepting new patients.

Stephen M. Szabo
Advanced in Liver Cancer
Dr. Stephen M. Szabo
Hematology | Oncology
Advanced in Liver Cancer
Dr. Stephen M. Szabo
Hematology | Oncology

Piedmont Oncology At Rockdale

1412 Milstead Ave NE, Ste 300, 
Conyers, GA 
 (20.2 miles away)
770-918-2320
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Szabo is board certified in hematology, medical oncology, and internal medicine. He completed his hematology-oncology training at Emory University Hospital and his internal medicine residency at the University of Michigan Hospitals. He earned his medical degree at Cornell University Medical College.Dr. Szabo has been practicing medicine for more than 20 years. Most recently, he was Chief of Staff at Emory St. Joseph Hospital. Prior to that, he was Chief of Staff at Emory Johns Creek Hospital and the Director of the Division of Community Oncology for the Department of Hematology Oncology at Emory Healthcare.Dr. Szabo has special interests in breast cancer, gastrointestinal cancer, and benign and malignant hematology. In his free time, Dr. Szabo enjoys promoting health education, hiking, sailing, and spending time with his family.Dr. Szabo and the team at Piedmont Oncology have the resources you need conveniently close to home.Dr. Szabo is accepting new patients and welcomes most major insurance plans. Dr. Szabo is rated as a Distinguished provider by MediFind in the treatment of Liver Cancer. His top areas of expertise are Hereditary Neuroblastoma, Inflammatory Breast Cancer, Gastric Lymphoma, Bone Marrow Aspiration, and Colonoscopy.

Jonathan C. Bender
Advanced in Liver Cancer
Dr. Jonathan C. Bender
Oncology | Hematology
Advanced in Liver Cancer
Dr. Jonathan C. Bender
Oncology | Hematology

Piedmont Cancer Institute, PC

1267 Highway 54 West, Suite 4200, 
Fayetteville, GA 
 (22.9 miles away)
678-829-1060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Bender is a Hematologist and an Oncologist in Fayetteville, Georgia. Dr. Bender is rated as a Distinguished provider by MediFind in the treatment of Liver Cancer. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia. Dr. Bender is currently accepting new patients.

VIEW MORE LIVER CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alese's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Alese is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Pancreatic Cancer
    Dr. Alese is
    Elite
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Distinguished
  • Appendix Cancer
    Dr. Alese is
    Distinguished
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Alese is
    Distinguished
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Familial Colorectal Cancer
    Dr. Alese is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Alese is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Gastrointestinal Stromal Tumor
    Dr. Alese is
    Distinguished
    . Learn about Gastrointestinal Stromal Tumor.
    See more Gastrointestinal Stromal Tumor experts
  • Lynch Syndrome
    Dr. Alese is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
View All 8 Distinguished Conditions
  • Advanced
  • Ampullary Cancer
    Dr. Alese is
    Advanced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Anal Cancer
    Dr. Alese is
    Advanced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Carcinoid Syndrome
    Dr. Alese is
    Advanced
    . Learn about Carcinoid Syndrome.
    See more Carcinoid Syndrome experts
  • Familial Prostate Cancer
    Dr. Alese is
    Advanced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Fibrolamellar Carcinoma
    Dr. Alese is
    Advanced
    . Learn about Fibrolamellar Carcinoma.
    See more Fibrolamellar Carcinoma experts
  • Gallbladder Adenocarcinoma
    Dr. Alese is
    Advanced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
View All 16 Advanced Conditions
  • Experienced
  • Adenoid Cystic Carcinoma
    Dr. Alese is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Adult Soft Tissue Sarcoma
    Dr. Alese is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Alese is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Alese is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Alveolar Soft Part Sarcoma
    Dr. Alese is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Bone Tumor
    Dr. Alese is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.